ArticleASM case reports2026
A case study of Powassan virus encephalitis in an immunocompromised host.
Article in ASM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Powassan virus (POWV) is a tick-borne, neurotropic arbovirus endemic to Canada and the United States and is transmitted by Ixodes ticks, which also carry Lyme disease. It is an increasingly recognized cause of neuro-invasive infection in humans, for which treatment is supportive. Prognosis in POWV encephalitis is variable, ranging from complete recovery to death. As with other arboviral encephalitides, the mainstay of diagnosis is serological testing. However, molecular diagnostics play an increasingly important role, particularly in the case of immunocompromised hosts. Case Summary: A 47-year-old woman with rheumatoid arthritis taking methotrexate experienced a tick bite, followed by target-shaped rash. She was clinically diagnosed with Lyme disease and started on doxycycline therapy. She then developed headache, ataxia, dysarthria, and diplopia. An extensive infectious workup was notable for positive Powassan virus IgM confirmed with neutralizing antibody testing several weeks later. CSF Powassan virus PCR was negative. She was treated empirically for neuroborreliosis and later with pulse-dose steroids and intravenous immunoglobulin (IVIG). She ultimately recovered after a 10-day hospitalization and 5 days of inpatient rehabilitation. Conclusion: Physicians should be aware of POWV, an underrecognized cause of encephalitis, and of the complexities in diagnostic testing. Notably, cross-reactive serologies are common in arboviral infection. Serological testing remains first line in diagnosis but requires confirmatory testing typically performed at reference laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.